The EEF2K Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human non-small cell lung adenocarcinoma cell line NCI-H1975. This product provides a loss-of-function model for the eukaryotic elongation factor 2 kinase (EEF2K) gene, enabling investigation of its role in translational control, stress responses, and cancer biology. The polyclonal pool ensures a heterogeneous knockout population, allowing functional studies without clonal selection bias. The CRISPR/Cas9-mediated gene disruption facilitates robust ablation of EEF2K expression, creating a versatile tool for downstream experimental analyses.
The host cell line, NCI-H1975, is an extensively characterized model of non-small cell lung adenocarcinoma, originally derived from a non-smoker female patient. This cell line harbors activating EGFR L858R and T790M mutations, representing a clinically relevant background for studying EGFR-targeted therapy resistance. As epithelial cells from a lung adenocarcinoma, NCI-H1975 retains key signaling and phenotypic features of the tumor microenvironment, making it an ideal host for investigating molecular mechanisms of NSCLC progression and drug sensitivity.
EEF2K is a calcium/calmodulin-dependent kinase that phosphorylates eukaryotic elongation factor 2 (EEF2) at threonine 56, inactivating it and thereby suppressing the elongation phase of protein synthesis. Its activity is tightly regulated by upstream kinases and signaling pathways: under nutrient deprivation or hypoxia, AMPK directly phosphorylates and activates EEF2K, while mTORC1, via S6K1, phosphorylates and inhibits EEF2K under growth-promoting conditions. Additional regulatory inputs include calcium/calmodulin binding, cAMP/PKA, and p38 MAPK. Once activated, EEF2K reduces global translation rates, promoting cell survival and autophagy as adaptive stress responses. It interacts with calmodulin and components of the mTORC1 and AMPK signaling complexes.
In the context of NCI-H1975 cells bearing EGFR L858R/T790M mutations, EEF2K-mediated translational arrest may contribute to acquired resistance against EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and osimertinib. By suppressing protein synthesis under therapeutic stress, EEF2K can enhance autophagy and promote cell survival, facilitating tumor cell adaptation. This polyclonal knockout model therefore enables dissection of EEF2K’s role in drug resistance, the unfolded protein response, and autophagy pathways in an EGFR-mutant NSCLC background. It provides a physiologically relevant system to evaluate whether EEF2K inhibition sensitizes cells to TKIs or other anticancer agents.
Researchers can employ these polyclonal knockout cells in a wide range of assays, including Western blotting for EEF2K and phospho-EEF2, cell viability and colony formation assays to assess proliferation, and drug sensitivity screens with osimertinib or erlotinib. Autophagy flux can be monitored via LC3-I/II conversion, while migration and invasion assays address metastatic potential. Transcriptomic analyses by RNA-seq and phospho-signaling investigations (e.g., phospho-AMPK, phospho-mTOR) further elucidate pathway alterations. This product is suitable for functional genomics studies, stress biology research, and translational cancer investigations. For further details or custom inquiries, please contact Ascent Research.
